Advertisement

Neue Aspekte in der Langzeitbehandlung schizophrener Patienten mit Neuroleptika

  • F. Müller-Spahn
Conference paper

Zusammenfassung

Eine effiziente langfristige Therapie unter dem Aspekt der Nutzen/Risiko-Abwägung ist neben der symptomsuppressiven Behandlung im Stadium der akuten Erkrankung vor allem für die Rezidivprophylaxe und damit die psychosoziale Integration von entscheidender Bedeutung. Während in früheren Jahren die Durchführung dieser Therapie zu den Hauptaufgaben von Nervenärzten gehörte, wird in jüngerer Zeit diese Behandlung zunehmend mehr von niedergelassenen Allgemeinärzten durchgeführt (Meller 1989).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bleuler M (1968) A 23-year longitudinal study of 208 schizophrenics and impressions in regard to nature of schizophrenia. In: Rosenthal D, Kety SS (eds) The transmission of schizophrenia. Pergamon Press, Oxford, pp 3–12Google Scholar
  2. Carpenter W, Heinrichs D, Alphs L (1985) Treatment of negative symptoms. Schizophr Bull 11 (3): 440–452PubMedGoogle Scholar
  3. Carpenter W Jr (1986) Early targeted pharmacotherapeutic Intervention in schizophrenia. J Clin Psychiatry 47/5 [Suppl]: 23–29Google Scholar
  4. Carpenter WT, Heinrichs DW, Hanlon TE (1987) A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry 144: 11: 1466–1470PubMedGoogle Scholar
  5. Cheung HK (1981) Schizophrenics fully remitted on neuroleptics for 3–5 years: To stop or continue drugs? Br J Psychiatry 138: 490–494PubMedCrossRefGoogle Scholar
  6. Chouinard G, Jones B (1980) Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacological characteristics. Am J Psychiatry 137: 16–21Google Scholar
  7. Ciompi C, Müller C (1976) Lebensweg and Alter der Schizophrenen. — Eine katamnestische Langzeitstudie bis ins Senium. Springer, Berlin Heidelberg New YorkGoogle Scholar
  8. Crow TJ, McMillan JF, Johnson AL, Johnstone EC (1986) The Northwick Park Study of first episodes of schizophrenia: II. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 148: 120–127Google Scholar
  9. Dencker SJ, Lepp M, Malm U (1980) Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study. Acta Psychiat Scand [Suppl] 279: 64–76Google Scholar
  10. Feinberg S, Kay S, Elijovich L, Fiszbein A, Opler L (1988) Pimozide treatment of the negative schizophrenic syndrome: An open trial. J Clin Psychiatry 49: 6: 235–241PubMedGoogle Scholar
  11. Hirsch SR, Gaind R, Rohde PD, Steven BC, Wing JK (1973) Outpatients maintenance of chronic schizophrenic patients with long-acting fluphenazine: A double-blind placebo trial. Br Med J 1: 633–637Google Scholar
  12. Hogarty E, Goldberg S, Schooler NR, Ulrich F (1974) Drug and sociotherapy in the aftercare of schizophrenic patients. Arch Gen Psychiatry 31: 603–608Google Scholar
  13. Hogarty GE, Ulrich RF, Mussare F, Aristigueta N (1976) Drug discontinuation among long-term successfully maintained schizophrenic outpatients. Dis New Syst 37: 494–500Google Scholar
  14. Huber G, Gross G, Schüttler R (1979) Schizophrenie. Eine Verlaufs-and sozialpsychiatrische Langzeitstudie. Springer, Berlin Heidelberg New YorkGoogle Scholar
  15. Johnson D, Pasterski G, Ludlow J, Street K, Taylor R (1983) The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: Drug and social consequences. Acta Psychiat Scand 67: 339–352Google Scholar
  16. Kane J (1987) Neuroleptic treatment of schizophrenia. In: Henn F, DeLisi L (eds) Handbook of schizophrenia, Vol 2. Elsevier, Amsterdam, pp 179–201Google Scholar
  17. Kane J, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J (1982) Fluphenazine versus placebo in patients with remitted, acute first schizophrenia. Arch Gen Psychiatry 39: 70–73PubMedGoogle Scholar
  18. Kane J, Rifkin A, Woerner M, Sarantakos S (1986) Dose response relationships in maintenance drug treatment for schizophrenia. Psychopharmacol Bull 6: 205–235Google Scholar
  19. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789–796PubMedGoogle Scholar
  20. Klein DF, Rosen B (1973) Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic inpatients. Arch Gen Psychiatry 29: 480–485PubMedGoogle Scholar
  21. Kolakowska T, Williams AO, Ardern M, Revely MA, Jambor K, Gelder MG, Mandelbrote BM (1985) Schizophrenia with good and poor outcome; I: early clinical features, response to neuroleptics and signs of organic dysfunction. Brit J Psychiatry 146: 229–246Google Scholar
  22. Marder SR, Putten T van, Mintz J, Lebelle M, McKenzie J, May P (1987) Low and conventional dose maintenance therapy with fluphenazine decanoate: two year outcome. Arch Gen Psychiatry 44: 518–521PubMedGoogle Scholar
  23. McCreadie R, Mackie M, Morrison D, Kidd J (1982) Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. Br J Psychiatry 140: 280–286PubMedCrossRefGoogle Scholar
  24. Meiler I (1989) Krankheitsverhalten in der Allgemeinbevölkerung: die Inanspruchnahme medizinischer und psychiatrischer Institutionen — Ergebnisse einer epidemiologischen Längsschnittstudie. Habilitationsschrift, MünchenGoogle Scholar
  25. Möller HJ, Scharl W, Zerssen D von (1985) Vorhersage des Therapieerfolges unter neuroleptischer Akutbehandlung: Ergebnisse einer empirischen Untersuchung an 243 stationär behandelten schizophrenen Patienten. Fortschr Neurol Psychiat 53: 370–383PubMedCrossRefGoogle Scholar
  26. Pietzcker A, Gaebel W, Köpcke W, Linden M, Müller P, Müller-Spahn F (1986) A german multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Pharmacopsychiatry 19: 161–166CrossRefGoogle Scholar
  27. Schooler NR, Levine J, Severe J, Brauzer B, DiMascio A, Klerman GL, Tuason V (1980) Prevention of relapse in schizophrenia. Arch Gen Psychiatry 37: 16–24Google Scholar
  28. Watt DC, Katz K, Shepherd M (1983) The natural history of schizophrenia: A 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol Med 13: 663–670PubMedCrossRefGoogle Scholar
  29. Wistedt B (1981) A depot neuroleptic withdrawal study. Acta Psychiatr Scand 64: 65–84PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • F. Müller-Spahn
    • 1
  1. 1.Psychiatrischen KlinikUniversität MünchenMünchen 2Deutschland

Personalised recommendations